Compare WEA & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEA | RPID |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.4M | 102.6M |
| IPO Year | N/A | 2021 |
| Metric | WEA | RPID |
|---|---|---|
| Price | $10.51 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 23.4K | ★ 209.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $10.30 | $1.58 |
| 52 Week High | $11.44 | $4.94 |
| Indicator | WEA | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 33.00 |
| Support Level | $10.46 | $1.66 |
| Resistance Level | $10.72 | $2.18 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 89.58 | 17.74 |
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.